Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Opening the adaptive toolbox.

Janet Wittes1, Peter A Lachenbruch

  • 1Statistics Collaborative, 1625 Massachusetts Ave., NW, Washington, DC 20036, USA. janet@statcollab.com

Biometrical Journal. Biometrische Zeitschrift
|September 16, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Menopausal Hormone Labels Should Rely on Evidence, Not Opinion.

JAMA·2026
Same author

Subgroups and Special Populations in Heart Failure Clinical Trials: Insights From the HFC-ARC Expert Consensus Panel.

JACC. Heart failure·2026
Same author

Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.

The New England journal of medicine·2025
Same author

Monitoring overall survival in pivotal trials in indolent cancers.

Statistics in biopharmaceutical research·2025
Same author

Response to Cleland and Anzar.

Clinical trials (London, England)·2025
Same author

Aspirin in primary prevention: Undue reliance on an uninformative trial led to misinformed clinical guidelines.

Clinical trials (London, England)·2025
Same journal

Comparison of Different Methods for the Meta-Analysis of Diagnostic Test Accuracy Studies-A Simulation Study.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

When to Adjust for Multiple Testing: A Unifying Guiding Principle.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

Ensuring Quality in Preclinical Research: The Importance of Being Human.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

Addressing Cluster-Level Treatment Effect Heterogeneity in Sample Size Determination for Hierarchical 2 × 2 Factorial Designs.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

A Multiple Imputation Approach to Distinguish Curative From Life-Prolonging Effects in the Presence of Missing Covariates.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

Tests for Categorical Data Beyond Pearson: A Distance Covariance and Energy Distance Approach.

Biometrical journal. Biometrische Zeitschrift·2026
See all related articles

This discussion reviews adaptive clinical trial designs, focusing on regulatory perspectives and biostatistical contributions. It highlights the importance of flexible trial designs for drug development and regulatory approval.

Area of Science:

  • Clinical Trials
  • Biostatistics
  • Regulatory Science

Background:

  • This special issue features three key papers discussing adaptive and flexible clinical trial designs.
  • The papers cover regulatory viewpoints, confirmatory trial methodologies, and the role of biostatistics in pharmaceutical innovation.

Discussion:

  • Examines 'A regulatory view on adaptive/flexible clinical trial design' by Hung et al.
  • Analyzes 'Confirmatory clinical trials with an adaptive design' by Koch.
  • Considers 'FDA's critical path initiative: A perspective on contributions of biostatistics' by O'Neill.

Key Insights:

  • Adaptive designs offer flexibility in clinical trials, potentially accelerating drug development.
  • Regulatory bodies are increasingly open to well-justified adaptive designs.

Related Experiment Videos

  • Biostatistics plays a crucial role in the design, analysis, and regulatory acceptance of these innovative trial structures.

    • Outlook:

    • Future clinical trials will likely incorporate more adaptive designs.
    • Continued collaboration between statisticians, regulators, and industry is essential.
    • Advancements in biostatistics will further enable efficient and ethical trial designs.